Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study.
10.3346/jkms.2014.29.1.90
- Author:
Mi Young LEE
1
;
Dong Seop CHOI
;
Moon Kyu LEE
;
Hyoung Woo LEE
;
Tae Sun PARK
;
Doo Man KIM
;
Choon Hee CHUNG
;
Duk Kyu KIM
;
In Joo KIM
;
Hak Chul JANG
;
Yong Soo PARK
;
Hyuk Sang KWON
;
Seung Hun LEE
;
Hee Kang SHIN
Author Information
1. Division of Endocrinology & Metabolism, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Publication Type:Original Article ; Clinical Trial ; Comparative Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Diabetes Mellitus, Type 2;
Acarbose;
Voglibose
- MeSH:
Acarbose/adverse effects/*therapeutic use;
Blood Glucose;
Diabetes Mellitus, Type 2/blood/*drug therapy;
Enzyme Inhibitors/adverse effects/therapeutic use;
Female;
Hemoglobin A, Glycosylated/analysis;
Humans;
Hypoglycemic Agents/adverse effects/therapeutic use;
Inositol/adverse effects/*analogs & derivatives/therapeutic use;
Insulin/*blood/therapeutic use;
Male;
Metformin/therapeutic use;
Middle Aged;
Prospective Studies;
alpha-Glucosidases/antagonists & inhibitors
- From:Journal of Korean Medical Science
2014;29(1):90-97
- CountryRepublic of Korea
- Language:English
-
Abstract:
We studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n=59, 300 mg/day) or voglibose (n=62, 0.9 mg/day). The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% +/- 0.71% to 7.71% +/- 0.93%) and voglibose groups (from 8.38% +/- 0.73% to 7.68% +/- 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 +/- 69.38 to 176.80 +/- 46.63 mg/dL) compared with the voglibose group (from 224.18 +/- 70.07 to 193.01 +/- 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin. (ClinicalTrials.gov number, NCT00970528)
